An IVF cycle involves several coordinated stages: ovarian stimulation to encourage multiple follicles to develop, close monitoring of that development through blood tests and ultrasound, and a final step to trigger the eggs within those follicles to complete maturation before they are retrieved. HCG is used at that final trigger step.
This role exists because hCG mimics the natural luteinizing hormone surge that would normally trigger ovulation in a non-stimulated cycle, a relationship explained in more depth in our article on hCG and LH sharing a receptor.
Natural LH has a very short half-life in the bloodstream, which makes it difficult to use reliably as a therapeutic trigger. HCG, because of its heavier glycosylation, persists in the body substantially longer, giving physicians a more predictable and controllable way to trigger the same biological process at a precisely chosen point in the treatment cycle.
This is the same underlying biochemistry discussed in our article on hCG biology in early pregnancy, applied here as a deliberate clinical tool rather than as a naturally occurring pregnancy signal.
Some fertility protocols use alternatives to hCG for this trigger step depending on the patient's specific risk profile, particularly where ovarian hyperstimulation syndrome risk is a concern. The choice of trigger agent is itself a clinical decision made by the treating physician rather than a fixed default applied to every cycle.
The timing of this trigger step is determined individually by the treating physician based on ultrasound follicle measurements and hormone levels specific to that patient and that cycle. It is never a fixed, generic schedule applied the same way to every patient, and it is administered only within a licensed fertility clinic setting.
This individualized, monitored structure is standard across IVF practice internationally and reflects the same regulatory framework covered in our overview of UAE fertility clinics and hCG regulation.
It is worth emphasizing that this trigger step is one component of a much larger fertility treatment process, involving multiple medications, extensive monitoring, and a multidisciplinary clinical team. HCG on its own does not constitute IVF treatment; it plays one specific, time-limited role within it.
In the UAE, IVF and fertility treatment can only be provided through licensed clinics operating under Ministry of Health and Prevention and emirate-level health authority oversight, discussed further in our regulatory status article.
REVIVE LAB UAE has no role in fertility treatment and supplies non-prescription research peptides for laboratory use only. REVIVE LAB UAE does not sell, stock, or supply hCG in any form.